CrystalO
CrystalO Biopharma is dedicated to advancing next-generation ion channel therapeutics. They are committed to the research and development of drugs for neurological and psychiatric disorders, chronic kidney diseases, and cardiovascular diseases.
Starpharma
Starpharma (ASX: SPL) is an ASX-listed biopharmaceutical company with over 20 years of dendrimer science expertise and a strong IP portfolio spanning 19 patent families and 150+ granted or pending patents. Its lead technology, the DEP® ADC Platform, is an advanced dendrimer-based approach that enhances antibody-drug conjugates by improving homogeneity, enabling higher and more controlled payload delivery, and expanding the therapeutic window for safer, more effective cancer treatments.
HEC
Sunshine Lake Pharmaceutical Co., Ltd. (also known as HEC Pharm; HKEX: 06887) is a fully integrated pharmaceutical company with a strong focus on infectious diseases, oncology, metabolic, and other chronic diseases. Established in 2005, HEC’s R&D center in Guangdong, China employs over 1,000 scientists and provides end-to-end drug discovery and development capabilities. HEC’s technology platforms span all major therapeutic modalities, including small molecules, oligonucleotides, peptides, antibodies, antibody–drug conjugates (ADCs), and cell therapies (CAR-T and stem cells). The company has three innovative drugs approved and a robust pipeline of more than 40 candidates at various stages of development, and is actively seeking global partnerships.
SalubrisBio
SalubrisBio is a US-based clinical-stage biotechnology company dedicated to discovering and developing complex biologics for cardiovascular disease and cancer. SalubrisBio is currently developing JK07, a novel antibody fusion in an ongoing global Phase 2 study for the treatment of heart failure, and JK06, a quadrivalent, biparatopic ADC targeting 5T4. Multiple preclinical programs in cardiovascular disease and cancer are advancing towards the clinic.
Jing Medicine
Jing Medicine is a clinical-stage biotech start-up with its primary operations in Shanghai, China. The company is focused on targeted protein degradation technology to address TKI drug resistance in oncology with its leading asset, HJ-004, on Osimertinib-resistant EGFR-mutant NSCLC. The asset is currently in a Phase Ia dose escalation study in China.
Sound Pharma
Sound Pharmaceuticals is a late-stage biotech focused on developing the first drugs to treat neurotologic diseases. SPI’s lead product, SPI-1005, is an oral small molecule (ebselen) with anti-inflammatory and neuroprotective properties that are unique and not immunosuppressive. SPI-1005 acts as a mimic of glutathione peroxidase I (GPx1) and induces GPx1 under redox stress and aging.
Immunophage
Nanjing Immunophage Biomedical Co., Ltd. is a clinical-stage biotechnology company founded in 2016, focusing on Innovative drug discovery and development for autoimmune diseases, oncology, metabolic diseases, and neurodegenerative disorders. The company targets the root causes of diseases to develop curative therapies. Immunophage has built a robust pipeline of global innovative assets. The pipeline includes IPG11406 (GPR183 antagonist), IPG1094 (MIF inhibitor), IPG7236 (CCR8 small molecule antagonist), IPG0521 (CCR8 mAb antagonist), IPG0916 (CCR6 mAb antagonist), IPG6620 (LPAR5 antagonist), and the other early discovery assets.
Sungen
Beijing Sungen Biomedical Technology is an innovation-driven biotech developing first- and best-in-class antibody therapies—powered by integrated AI discovery and advanced CMC capabilities—to address major unmet medical needs.
NRT
Chengdu New Radiomedicine Technology Co., Ltd. (“NRT”), founded by veterans in nuclear technology, focuses on the full value chain of medical isotopes production and radiopharmaceutical innovation. The company was founded in 2016 with multiple branches in China and global presence in the United States and Australia. Our team of 300+ professionals delivers integrated solutions from radiopharmaceutical discovery to global commercialization.
Leveraging rich expertise in nuclear medicine and drug innovation, our cross-disciplinary team of radiochemists, clinical researchers and regulatory experts work together to accelerate radioligand therapy (RLT) advancement. The iCleave™ Technology develops purposely-designed linkers for RLT, optimizing bio-distribution, safety, and efficacy. The 68Ga- and 177Lu-NRT6020 Injections for diagnosis and treatment of FAP positive advanced solid tumors, respectively, have obtained FDA IND clearance and NMPA IND approval, with Phase I patient enrollment in progress.
Additionally, NRT has completed installation of the first 30MeV Cyclone® IKON in Asia at and is ready for production of important therapeutic and imaging isotopes.
NRT is committed to becoming a leading enterprise in the field of innovative radiopharmaceutical development.
Virion Therapeutics
Virion Therapeutics, LLC is a clinical-stage company developing novel immunotherapies that utilize proprietary checkpoint modifiers to enhance/restore, broaden, and elicit sustained immune responses, with the goal of curing cancer and chronic infectious diseases. Virion has since developed a robust pipeline, including its lead VRON-0200 clinical program, and several additional IND-enabling programs, such as its VRON-0300 oncology program for advanced solid tumors, leveraging its proprietary platform technologies.
Affinity
Affinity is a biotechnology company focused on developing next-generation tumor-activated therapeutics for oncology. Its proprietary TMEA platform employs a tumor-specific cleavable masking peptide to keep drugs inactive systemically and selectively activate them within the tumor microenvironment, significantly reducing off-target toxicity. Based on this platform, Affinity is advancing a diversified pipeline spanning TMEA-ADCs (including DXd and dual-payload programs), tumor-activated CD3 bispecifics (TMEA-TCEs), TME-focused immunotherapies (PD-1/IL-2, IL-2, CTLA-4, CD47), and tumor-activated chemotherapies such as doxorubicin and paclitaxel.
Oncoinvent
Oncoinvent ASA is a clinical-stage biotech company with a vision to transform cancer care through direct alpha therapy. The company’s lead product candidate, Radspherin®, is an innovative internal radiation therapy designed to directly target microscopic metastases in the abdominal cavity following surgery.
Huilun Pharma
Huilun is a high-tech enterprise focused on R&D and technical services in the area of innovative small molecule medicine and generic drugs. Its therapeutic focus spans oncology, gynecology, CNS, inflammation/respiratory, and cardiovascular diseases.
Livzon
Livzon Pharmaceutical Group (Livzon) is a wholly-owned subsidiary of Joincare Pharmaceutical Group Co., Ltd, and is a large comprehensive pharmaceutical group engaged in pharmaceutical R&D, production, and commercialization. Livzon is also a dual-listed pharmaceutical company on the Shenzhen Stock Exchange and the Hong Kong Stock Exchange. Livzon’s portfolio includes over 100 products that are currently on the market or in various stages of development. These products cover therapeutic areas such as Metabolic, Psychiatry & Neurology, Cardio-cerebrovascular, Anti-Infection, Reproduction, and Respiratory & Immune Diseases, among others. Our distribution channels have covered over 90% of hospitals in China. In 2024, the company achieved revenue of USD 1.661 billion and a net profit of USD 278 million.
EnnovaBio
Shanghai EnnovaBio Pharmaceuticals Co., Ltd. is a clinical-stage biotech company led by a group of seasoned drug discovery and development scientists, focusing on delivering first-in-class treatments for inflammation and metabolic complications with key differentiations. Powered by systems biology-guided disease characterization and target discovery with cutting-edge computational technologies, EnnovaBio has built an innovative drug discovery and development pipeline. Currently, multiple projects, including EnnovaBio’s proprietary first-in-class oral small-molecule therapy for diabetic macular edema (DME) and cardiac surgery-associated acute kidney injury (CSA-AKI) have advanced into Phase II clinical development with promising therapeutic potential indicated.
Nuphase
Nuphase was established in 2022, a world-leading drug discovery biotech equipped with first–in–class biomolecular condensate (or liquid-liquid phase separation) driven innovative platforms. The company is registered in Hangzhou with two research centers in Shanghai and Beijing to distinguish itself from other phase separation companies with our own first-in-class two cutting-edge platforms.
Leading Tac
Leadingtac is a start-up biotech company founded in late 2019 by several experienced drug explorers and focused on the new, promising yet challenging modality of Targeted Protein Degradation (TPD). Leadingtac is located at the center of the life-science cluster in China, ZhangJiang Pharmaceutical Valley, Shanghai, to embrace the most advanced science in drug discovery. Leadingtac is committed to the discovery and development of new drugs for the treatment of oncology and autoimmune-related diseases.
DIAO
Chengdu DIAO Pharmaceutical Group Co., Ltd. was established in 1988 and is headquartered in Chengdu, China. It is a domestic integrated pharmaceutical group established by an experienced team, focusing on research and development (R&D) of pharmaceuticals. The group has 4 pharmaceutical companies with annual sales of around 4 billion RMB and an asset value of approximately 7 billion RMB.
Lingyi Biotech
Lingyi Biotech is a clinical-stage biotech company and an innovative leader in the global field of monogenic disease therapy, focusing on critical clinical needs such as metabolic and central nervous system disorders. By leveraging the world’s first regulatable CREATETM gene expression system and an AI-integrated vector design approach, the company is advancing next-generation regulable AAV gene therapy technology (AAV2.0). It has established four core technology platforms covering AAV2.0 vector design, precision-targeted delivery systems, rare disease animal models, and GMP-compliant manufacturing. These platforms enable breakthroughs in key areas, including novel vector development, targeted delivery, and efficient production processes.
Akeylink
Akeylink Biotechnology was established in 2021 in Shanghai, China, with a focus on developing novel drugs for treating viral infections and liver-related diseases. Akeylink is a spin-out company from Cosunter Pharmaceutical (广生堂), a publicly listed company on the Shenzhen Stock Exchange (ticker symbol: 300436), engaging in the development and commercialization of generic drugs.
The company focuses on antiviral and liver disease treatments, with a strategically optimized product pipeline for both short- and long-term growth. Its oral small-molecule drug for COVID-19, Tazovid®, a best-in-class 3CL protease inhibitor, has been approved and launched in China in 2023, contributing to the nation’s pandemic response. Another prime asset of the company, GST-HG141, a novel first-in-class oral HBV capsid assembly modulator (CAM) for the treatment of chronic hepatitis B, has shown excellent efficacy and safety results in Phase 2 clinical trials and has successfully advanced to Phase 3. Additionally, GST-HG131, a first-in-class oral HBsAg inhibitor for the treatment of chronic hepatitis B, has displayed excellent tolerability and safety profile in a Phase 1 clinical trial and demonstrated robust efficacy in reducing HBsAg levels in a Phase 2 study. It is currently progressing rapidly into Phase 2B/3 studies as a mono- or combination therapy.
Stand Up Therapeutics
Stand Up Therapeutics Inc. is a Seoul-based biotech company developing next-generation in vivo gene therapies for neurological diseases. Using proprietary Direct Lineage Reprogramming (DLR) and Cell Resetting Technology (CRT), we aim to regenerate functional neurons directly within the central nervous system. Our lead program, STUP-001, is the world’s first in vivo direct cell conversion gene therapy to enter a first-in-human trial for chronic spinal cord injury (MFDS-approval IIT, Phase I/II). Our second program, STUP-002, applies CRT to Parkinson’s disease and is currently at the non-clinical stage
Aptabio
AptaBio develops innovative treatments for intractable diseases using proprietary platform technologies in oxidative-stress modulation, CAF conditioning, and aptamer-drug conjugates that address fundamental drivers of inflammation, fibrosis, and cancer resistance.
Samjin Pharm
Samjin is dedicated to advancing therapeutic breakthroughs. We focus on developing innovative treatments for diseases with high unmet medical needs, particularly those that are difficult to treat and pose significant challenges, including various cancers, immune disorders, and obesity. We maintain a dynamic and diverse R&D pipeline, utilizing multiple modalities, including small-molecules, ADCs, and TPDs. We actively foster open innovation through strategic partnerships with domestic and global companies.
Bilix
Bilix Co., Ltd is a clinical-stage biotech company developing Brixelle, the world’s first synthetic PEGylated bilirubin nanoparticle for ischemia-reperfusion injury (IRI) and organ protection. We are harnessing the therapeutic power of bilirubin to create novel drugs, employing diverse strategies to target a wide range of indications.
Ubix Therapeutics
Ubix Therapeutics is a clinical-stage biotechnology company focused on developing heterobifunctional degrader drugs, collectively known as Targeted Protein Degradation (TPD) therapeutics, with a primary emphasis on oncology. Its lead asset, UBX-303-1, is currently in a Phase 1a dose-escalation trial and has demonstrated good tolerability as well as early signs of efficacy at the first two dose levels.
Idience
Idience Co. Ltd. (“Idience’) is a clinical-stage biotech company pursuing novel therapeutics for cancer with high unmet medical needs. We were established in 2019 by Ildong Holdings Group, one of the leading pharmaceutical and healthcare groups in South Korea.
Vcare
Jiangsu Vcare PharmaTech Co., Ltd.(Jiangsu Vcare), established in 2010, is a high-tech biopharmaceutical company dedicated to addressing unmet clinical needs through differentiated innovation in drug and advanced therapy development. Since our inception, we’ve experienced rapid growth and evolved into a group-style enterprise with a strong foundation in two core business segments: innovative drug R&D and comprehensive pharmaceutical industry chain services. With 15 years of experience and a forward-looking mindset, Jiangsu Vcare continues to shape the future of biopharma through technology, quality, and purpose-driven innovation.
BioToChina.org 